|
1.Erdogan A, Davidson CJ. Recent clinical trials of iodixanol. Rev Cardiovasc Med 2003;4 Suppl 5:S43-50. 2.Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320(3):143-9. 3.McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003;4 Suppl 5:S3-9. 4.Guitterez NV, Diaz A, Timmis GC, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 2002;15(5):349-54. 5.Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. Rev Cardiovasc Med 2003;4 Suppl 1:S7-S14. 6.Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology 1997;203(3):605-10. 7.Conti CR. Cardiovascular happenings in Europe. Clin Cardiol 2000;23(7):471-2. 8.Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105(19):2259-64. 9.Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983;74(2):243-8. 10.Behrend T, Miller SB. Acute renal failure in the cardiac care unit: etiologies, outcomes, and prognostic factors. Kidney Int 1999;56(1):238-43. 11.Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. Jama 1996;275(19):1489-94. 12.McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103(5):368-75. 13.Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH. Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993;44(6):1217-23. 14.Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 1992;41(5):1408-15. 15.Yoshioka K, Murakami K, Maki S. [Growth factors: a regulator of renal function]. Nippon Rinsho 1992;50(12):2931-6. 16.Bakris GL, Gaber AO, Jones JD. Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology 1990;175(1):57-60. 17.Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331(21):1416-20. 18.Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188(1):171-8. 19.Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47(1):254-61. 20.Aspelin P. [Reduced risk of nepropathy with isoosmolar contrast media]. Lakartidningen 2003;100(23):2067-8. 21.Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40(2):298-303. 22.Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362(9384):598-603. 23.Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349(14):1333-40. 24.Kohn LT, J. M. Corrigan and M. S. Donaldson. To Err is Human: Building a Safer Health System. Institute of Medicine Report.: Washington, DC: National Academy Press; 2000. 25.林宏榮. 病患安全風險因素之研究—以台灣大型醫院急診部門為例: 成大; 2003. 26.Altman DE, Clancy C, Blendon RJ. Improving Patient Safety—Five Years after the IOM Report. New England Journal of Medicine 2004;351:2041-3. 27.Leape LL, Berwick DM. Five years after To Err Is Human: what have we learned. JAMA 2005;293(19):2384-90. 28.Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 2003;163(12):1409-16. 29.Barker KN, Mikeal RL, Pearson RE, Illig NA, Morse ML. Medication errors in nursing homes and small hospitals. Am J Hosp Pharm 1982;39(6):987-91. 30.Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. Jama 1995;274(1):29-34. 31.Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 1997;25(8):1289-97. 32.Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. Jama 1995;274(1):35-43. 33.Bates DW, Teich JM, Lee J, et al. The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc 1999;6(4):313-21. 34.Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998;280(15):1311-6. 35.Burton ME, Ash CL, Hill Jr DP, Handy T, Shepherd MD, Vasko MR. A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. Clin Pharmacol Ther 1991;49(6):685-94. 36.Casner PR, Reilly R, Ho H. A randomized controlled trial of computerized pharmacokinetic theophylline dosing versus empiric physician dosing. Clin Pharmacol Ther 1993;53(6):684-90. 37.Evans RS, Classen DC, Pestotnik SL, Lundsgaarde HP, Burke JP. Improving empiric antibiotic selection using computer decision support. Archives of Internal Medicine 1994;154(8):878-84. 38.Evans RS, Pestotnik SL, Ph R, et al. A Computer-Assisted Management Program for Antibiotics and Other Antiinfective Agents. New England Journal of Medicine. 39.Hurley SF, Dziukas LJ, McNeil JJ, Brignell MJ. A randomized controlled clinical trial of pharmacokinetic theophylline dosing. Am Rev Respir Dis 1986;134(6):1219-24. 40.In RA. Guided Medication Dosing for Inpatients With Renal Insufficiency. JAMA 2001;286:2839-44. 41.Mungall DR, Anbe D, Forrester PL, et al. A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram--directed heparin therapy. Clin Pharmacol Ther 1994;55(5):591-6. 42.Overhage JM, Tierney WM, Zhou XHA, McDonald CJ. A Randomized Trial of" Corollary Orders" to Prevent Errors of Omission. Journal of the American Medical Informatics Association 1997;4:364-75. 43.Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW. Effects of computerized physician order entry on prescribing practices. Arch Intern Med 2000;160(18):2741-7. 44.White RH, Hong R, Venook AP, et al. Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing. J Gen Intern Med 1987;2(3):141-8. 45.Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 2005;293(10):1223-38. 46.記者:廖宗慶. 少女注射顯影劑死 疑醫療疏失. TVBS 2005/6/23. 47.記者:簡東源. 服下顯影劑不治 死因待查. 中國時報 2005/08/05. 48.Sittig DF, Krall M, Kaalaas-Sittig J, Ash JS. Emotional Aspects of Computer-based Provider Order Entry: A Qualitative Study. J Am Med Inform Assoc 2005. 49.Fitzpatrick J, Koh JS. If you build it (right), they will come: the physician-friendly CPOE. Not everything works as planned right out of the box. A Mississippi hospital customizes its electronic order entry system for maximum use by physicians. Health Manag Technol 2005;26(1):52-3. 50.Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med 2003;348(25):2526-34. 51.Kremsdorf R. CPOE: not the first step toward patient safety. Health Manag Technol 2005;26(1):66, 5.
|